New York, NY (Press Release) – Phosplatin Thera­peutics LLC, a clin­i­cal stage pharma­ceu­tical com­pany focused on on­col­ogy thera­peutics, to­day an­nounced that the United States Patent and Trade­mark Office (USPTO) has issued US Patent No. 10,668,080, entitled: "Phosphaplatin Compounds as Thera­peutics Agents for Treatment of Bone or Blood Cancers." The granted claims are directed to the use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes, in­clu­sive of the Com­pany's lead com­pound, PT-112, as thera­peutic agents for the treat­ment of bone and blood can­cers, such as mul­ti­ple myeloma, or solid tumor can­cers that metastasize to bone, such as …

New York, NY (Press Release) – Phosplatin Thera­peutics LLC, a clin­i­cal stage pharma­ceu­tical com­pany focused on on­col­ogy drug devel­op­ment, an­nounced to­day it has en­rolled the first cohort of patients into its Phase I / II study of PT-112 as a single agent in re­lapsed or re­frac­tory mul­ti­ple myeloma. The Com­pany fur­ther an­nounced having re­ceived FDA Orphan Drug Desig­na­tion for PT-112 in the treat­ment of mul­ti­ple myeloma.

PT-112 is cur­rently under ad­vanced Phase I devel­op­ment in solid tumors. As re­ported at the ASCO 2017 Annual Meeting, PT-112 dis­plays an attractive tol­er­a­bil­ity profile and signals …